FDA opioid adcomm chair blasts agency for 'willful blindness that borders on the criminal'
In scathing remarks directed at the FDA’s handling of opioid approvals, the head of the agency’s advisory panel has lambasted its “cozy, cozy relationships” with the pharmaceutical industry and called for a halt in considering any new opioids for approval.
Raeford Brown, chair of the FDA’s anesthetic and analgesic drug products advisory committee, did not pull any punches in his interview with the Guardian:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.